bd2-selective bet inhibitor nuv-868
Generic: BD2-selective BET Inhibitor NUV-868
bd2-selective bet inhibitor nuv-868: 1 clinical trial tracked.
bd2-selective bet inhibitor nuv-868 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage context preserved
Prepared research question
What is verified about bd2-selective bet inhibitor nuv-868, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (1)
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Primary endpoint: Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D)
Interventionalopen82 targetStarted 2022-03Completion 2024-0722 sites · Australia, United StatesNuvation Bio Inc.